Umecrine Cognition will attend BIO-Europe Spring® 2025 in Milan
Prenumeration
STOCKHOLM – March 19, 2025. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Milan, Italy. The meeting takes place March 17–19th and is expected to gather more than 3,700 attendees representing the global life science industry. At the meeting, Umecrine Cognition will share information about the ongoing Phase 2 clinical trial of its lead drug candidate, golexanolone, in primary biliary cholangitis (PBC), targeting patients experiencing central fatigue. Furthermore, the company will outline its ongoing development activities in Parkinson’s disease (PD).
BIO-Europe is an annual premier partnering event in the global life science community. It gathers company executives and representatives from around the world to promote scientific and business collaborations. Anders Karlsson, CEO of Umecrine Cognition, and Magnus Doverskog, Senior Vice President and Chief Scientific Officer, will attend the meeting.
Umecrine Cognition is making significant and exciting progress in developing its lead drug candidate golexanolone, which targets severe fatigue and cognitive impairment in PBC and Parkinson’s disease. At the end of 2024, the company presented positive results from the first part of the ongoing Phase 1/2 study (Part A) at the AASLD meeting in San Diego. The study is now recruiting patients into phase 2a study (Part B) in eight countries in Europe. In parallel, further preclinical data support the ameliorating role of golexanolone in Parkinson’s Disease, showing its promise in improving both motor and non-motor symptoms.
“We look forward to engaging in constructive dialogues with potential commercial partners in the pharma industry and with the investor community at this year’s BIO-Europe Spring, where we will share our recent progress in the development of Umecrine Cognition’s first-in-class drug candidate golexanolone. We anticipate busy days ahead, as interest in golexanolone and its mechanism of action is steadily increasing in line with the growing body of preclinical literature that points at its potential to inhibit neuroinflammation and normalize neural signaling in both PBC and Parkinson’s disease,” says Anders Karlsson, CEO of Umecrine Cognition.
For further information, please contact:
Anders Karlsson, CEO, Umecrine Cognition AB
Phone: +46 70 – 918 00 10, e-mail: anders.karlsson@umecrine.se
About Umecrine Cognition AB
Umecrine Cognition AB develops a completely new class of pharmaceuticals against neurological disturbances in the brain that may arise as a consequence of several underlying diseases, leading to strongly reduced cognitive functions and wakefulness. Results from an internationally recognized clinical Phase 2 study indicates that the company’s most advanced drug candidate, golexanolone, normalizes the brain’s signaling and improves cognition as well as wakefulness in patients diagnosed with hepatic encephalopathy. The continued drug development will initially focus on patient groups whose symptoms arise from chronic liver diseases. The mode of action is however relevant in a number of other indications. For more information, visit www.umecrinecognition.com.